Share Price and Basic Stock Data
Last Updated: December 27, 2025, 9:34 pm
| PEG Ratio | 3.23 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Neuland Laboratories Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹19,217 Cr and a share price of ₹14,978. The company reported sales of ₹1,191 Cr for the fiscal year ending March 2023, increasing to ₹1,559 Cr for March 2024. However, preliminary figures for March 2025 show a slight decline in revenue to ₹1,477 Cr. Quarterly sales in FY 2024 demonstrated variability, with a peak of ₹440 Cr in June 2024, followed by a drop to ₹311 Cr in September 2024. The sales trajectory reflects fluctuations influenced by market conditions and operational challenges. Despite these variances, the trailing twelve months (TTM) sales stood at ₹1,533 Cr, indicating a robust performance overall. The company’s revenue from operations per share was reported at ₹1,144.79, showcasing its operational efficiency and market penetration.
Profitability and Efficiency Metrics
Neuland Laboratories has characterized its profitability through consistent operating profit margins (OPM), which stood at 12% overall, with quarterly fluctuations peaking at 33% in September 2023. The operating profit for FY 2023 was recorded at ₹273 Cr, while FY 2024 saw a significant rise to ₹463 Cr. However, the preliminary figures for FY 2025 indicate a decline to ₹331 Cr. The net profit margin was reported at 17.61% for March 2025, reflecting an effective cost management strategy, although this is lower than the previous year’s margin of 19.25%. The interest coverage ratio (ICR) was exceptionally high at 41.43x, demonstrating the company’s ability to comfortably meet its interest obligations. Overall, the performance metrics highlight Neuland’s operational strengths, but the declining net profit trend raises questions regarding future profitability sustainability.
Balance Sheet Strength and Financial Ratios
Neuland Laboratories’ balance sheet reflects a solid foundation, with total assets amounting to ₹2,180 Cr as of March 2025. The company reported reserves of ₹1,607 Cr, indicating a strong retained earnings position. Borrowings stood at ₹265 Cr, resulting in a low total debt-to-equity ratio of 0.08x, emphasizing the company’s conservative leverage strategy. The current ratio was recorded at 2.45, indicating strong liquidity and the ability to cover short-term liabilities. The book value per share was reported at ₹1,181.32, suggesting that the shares are trading at a price-to-book value ratio of 10.22x, which is significantly higher than typical sector averages. This high valuation could indicate market confidence but also poses a risk if earnings do not meet investor expectations. The cash conversion cycle (CCC) was recorded at 160 days, reflecting efficient working capital management.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Neuland Laboratories indicates a diverse investor base, with promoters holding 32.64% of the company as of September 2025. Foreign Institutional Investors (FIIs) maintained a stake of 20.60%, while Domestic Institutional Investors (DIIs) held 13.55%. The public shareholding accounted for 32.80%. Over the past years, there has been a gradual decline in promoter holdings, which may signal a shift in control dynamics. However, the increase in FII participation from 17.70% in December 2022 to 22.69% in December 2023 reflects growing international interest in the company. The number of shareholders rose to 44,393, indicating enhanced retail investor engagement. This diverse distribution of ownership can bolster investor confidence, although the declining promoter stake may raise concerns about long-term strategic direction.
Outlook, Risks, and Final Insight
The outlook for Neuland Laboratories presents a mixed scenario. The company has demonstrated strong operational metrics and profitability ratios, supported by a healthy balance sheet. However, potential risks include the declining sales trend and net profit margins, which may affect future growth prospects. Additionally, the high price-to-earnings ratio of 98.1 suggests that the stock may be overvalued if earnings do not grow accordingly. The volatility in quarterly sales and the cash conversion cycle also warrant monitoring. Future strategies should focus on stabilizing revenue growth and enhancing margins to satisfy investor expectations. If the company successfully navigates these challenges, it could solidify its position as a leading player in the pharmaceuticals sector, but failing to do so may lead to increased scrutiny from investors.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,105.46 Cr | 1,149.90 | 52.70 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 221 | 294 | 269 | 407 | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 |
| Expenses | 193 | 224 | 215 | 287 | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 |
| Operating Profit | 29 | 69 | 54 | 120 | 97 | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 |
| OPM % | 13% | 24% | 20% | 29% | 27% | 33% | 31% | 28% | 28% | 20% | 22% | 16% | 12% |
| Other Income | 1 | 0 | 1 | 8 | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 |
| Interest | 3 | 3 | 3 | 4 | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 |
| Depreciation | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 |
| Profit before tax | 13 | 53 | 39 | 110 | 83 | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 |
| Tax % | 26% | 28% | 22% | 23% | 26% | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% |
| Net Profit | 10 | 38 | 31 | 85 | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 |
| EPS in Rs | 7.77 | 29.98 | 23.81 | 65.89 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.68 | 10.83 |
Last Updated: August 1, 2025, 4:25 pm
Below is a detailed analysis of the quarterly data for Neuland Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 293.00 Cr.. The value appears to be declining and may need further review. It has decreased from 328.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 35.00 Cr..
- For Expenses, as of Jun 2025, the value is 258.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 277.00 Cr. (Mar 2025) to 258.00 Cr., marking a decrease of 19.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2025) to 34.00 Cr., marking a decrease of 17.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 12.00%, marking a decrease of 4.00%.
- For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 21.00 Cr..
- For Tax %, as of Jun 2025, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 21.00%, marking a decrease of 8.00%.
- For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 10.83. The value appears to be declining and may need further review. It has decreased from 21.68 (Mar 2025) to 10.83, marking a decrease of 10.85.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:54 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 1,533 |
| Expenses | 395 | 402 | 430 | 472 | 477 | 608 | 661 | 790 | 807 | 918 | 1,096 | 1,146 | 1,206 |
| Operating Profit | 71 | 67 | 80 | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 463 | 331 | 328 |
| OPM % | 15% | 14% | 16% | 18% | 10% | 9% | 13% | 16% | 15% | 23% | 30% | 22% | 21% |
| Other Income | 3 | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 12 | 90 | 77 |
| Interest | 25 | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 14 | 13 | 14 | 8 | 15 |
| Depreciation | 15 | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 | 76 |
| Profit before tax | 35 | 25 | 42 | 67 | 14 | 20 | 53 | 105 | 82 | 216 | 401 | 346 | 314 |
| Tax % | 23% | 36% | 36% | 30% | 13% | 19% | 69% | 23% | 22% | 24% | 25% | 25% | |
| Net Profit | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 240 |
| EPS in Rs | 30.12 | 17.96 | 30.75 | 52.74 | 13.57 | 12.81 | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 187.18 |
| Dividend Payout % | 9% | 8% | 7% | 0% | 0% | 0% | 16% | 8% | 10% | 8% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -40.74% | 68.75% | 74.07% | -74.47% | 33.33% | 0.00% | 406.25% | -20.99% | 156.25% | 82.93% | -13.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 109.49% | 5.32% | -148.54% | 107.80% | -33.33% | 406.25% | -427.24% | 177.24% | -73.32% | -96.26% |
Neuland Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 14% |
| 3 Years: | 16% |
| TTM: | -19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 67% |
| 3 Years: | 47% |
| TTM: | -59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 71% |
| 3 Years: | 130% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 16% |
| 3 Years: | 19% |
| Last Year: | 15% |
Last Updated: September 5, 2025, 11:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:43 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 116 | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 | 1,512 | 1,607 |
| Borrowings | 190 | 188 | 182 | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 95 | 157 | 265 |
| Other Liabilities | 169 | 162 | 155 | 148 | 194 | 200 | 257 | 356 | 302 | 457 | 454 | 498 | 649 |
| Total Liabilities | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,534 |
| Fixed Assets | 131 | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 | 955 | 1,076 |
| CWIP | 35 | 41 | 40 | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 48 | 140 |
| Investments | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 | 114 |
| Other Assets | 311 | 340 | 337 | 393 | 463 | 476 | 547 | 585 | 592 | 781 | 962 | 1,068 | 1,204 |
| Total Assets | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 | 2,534 |
Below is a detailed analysis of the balance sheet data for Neuland Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,607.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,512.00 Cr. (Mar 2025) to 1,607.00 Cr., marking an increase of 95.00 Cr..
- For Borrowings, as of Sep 2025, the value is 265.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 157.00 Cr. (Mar 2025) to 265.00 Cr., marking an increase of 108.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 649.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 498.00 Cr. (Mar 2025) to 649.00 Cr., marking an increase of 151.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,534.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,180.00 Cr. (Mar 2025) to 2,534.00 Cr., marking an increase of 354.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,076.00 Cr.. The value appears strong and on an upward trend. It has increased from 955.00 Cr. (Mar 2025) to 1,076.00 Cr., marking an increase of 121.00 Cr..
- For CWIP, as of Sep 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 48.00 Cr. (Mar 2025) to 140.00 Cr., marking an increase of 92.00 Cr..
- For Investments, as of Sep 2025, the value is 114.00 Cr.. The value appears strong and on an upward trend. It has increased from 109.00 Cr. (Mar 2025) to 114.00 Cr., marking an increase of 5.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,204.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,068.00 Cr. (Mar 2025) to 1,204.00 Cr., marking an increase of 136.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,534.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,180.00 Cr. (Mar 2025) to 2,534.00 Cr., marking an increase of 354.00 Cr..
Notably, the Reserves (1,607.00 Cr.) exceed the Borrowings (265.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -119.00 | -121.00 | -102.00 | -86.00 | -268.00 | -173.00 | -162.00 | -35.00 | -97.00 | 145.00 | 368.00 | 174.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 100 | 85 | 114 | 134 | 90 | 91 | 85 | 90 | 111 | 87 | 78 |
| Inventory Days | 138 | 170 | 182 | 186 | 266 | 191 | 209 | 205 | 227 | 211 | 220 | 238 |
| Days Payable | 139 | 167 | 121 | 118 | 189 | 118 | 110 | 126 | 100 | 129 | 121 | 156 |
| Cash Conversion Cycle | 92 | 103 | 147 | 182 | 211 | 162 | 190 | 164 | 216 | 193 | 187 | 160 |
| Working Capital Days | -21 | 11 | 26 | 44 | 38 | 44 | 49 | 60 | 74 | 81 | 88 | 76 |
| ROCE % | 19% | 16% | 18% | 16% | 4% | 4% | 8% | 11% | 10% | 21% | 33% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Flexicap Fund | 270,843 | 2.33 | 468.23 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 161,718 | 1.73 | 279.58 | 166,718 | 2025-12-14 08:14:20 | -3% |
| Mahindra Manulife Small Cap Fund | 64,583 | 2.64 | 111.65 | N/A | N/A | N/A |
| Mahindra Manulife Multi Cap Fund | 55,227 | 1.56 | 95.48 | 36,000 | 2025-12-13 07:59:26 | 53.41% |
| Bandhan Small Cap Fund | 54,813 | 0.52 | 94.76 | 59,213 | 2025-12-15 06:52:35 | -7.43% |
| Sundaram Small Cap Fund | 44,855 | 2.25 | 77.55 | N/A | N/A | N/A |
| Mahindra Manulife Large & Mid Cap Fund | 27,800 | 1.72 | 48.06 | N/A | N/A | N/A |
| ITI Small Cap Fund | 25,861 | 1.59 | 44.71 | N/A | N/A | N/A |
| PGIM India Flexi Cap Fund | 25,605 | 0.69 | 44.27 | N/A | N/A | N/A |
| HSBC Focused Fund | 25,000 | 2.51 | 43.22 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
| Diluted EPS (Rs.) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
| Cash EPS (Rs.) | 252.44 | 278.89 | 167.66 | 87.49 | 93.26 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1181.32 | 993.65 | 769.94 | 650.88 | 608.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1181.97 | 994.31 | 770.59 | 651.52 | 609.63 |
| Revenue From Operations / Share (Rs.) | 1144.79 | 1208.16 | 923.37 | 737.24 | 726.26 |
| PBDIT / Share (Rs.) | 266.48 | 368.31 | 218.28 | 112.16 | 126.29 |
| PBIT / Share (Rs.) | 215.67 | 322.03 | 177.37 | 74.15 | 95.52 |
| PBT / Share (Rs.) | 268.46 | 311.18 | 167.24 | 63.69 | 81.65 |
| Net Profit / Share (Rs.) | 201.63 | 232.61 | 126.75 | 49.47 | 62.50 |
| NP After MI And SOA / Share (Rs.) | 201.63 | 232.61 | 126.75 | 49.47 | 62.50 |
| PBDIT Margin (%) | 23.27 | 30.48 | 23.63 | 15.21 | 17.38 |
| PBIT Margin (%) | 18.83 | 26.65 | 19.20 | 10.05 | 13.15 |
| PBT Margin (%) | 23.45 | 25.75 | 18.11 | 8.63 | 11.24 |
| Net Profit Margin (%) | 17.61 | 19.25 | 13.72 | 6.71 | 8.60 |
| NP After MI And SOA Margin (%) | 17.61 | 19.25 | 13.72 | 6.71 | 8.60 |
| Return on Networth / Equity (%) | 17.06 | 23.40 | 16.46 | 7.60 | 10.26 |
| Return on Capital Employeed (%) | 16.23 | 29.57 | 20.05 | 9.37 | 12.88 |
| Return On Assets (%) | 11.93 | 16.37 | 10.35 | 4.61 | 6.08 |
| Long Term Debt / Equity (X) | 0.05 | 0.03 | 0.07 | 0.12 | 0.11 |
| Total Debt / Equity (X) | 0.08 | 0.06 | 0.12 | 0.27 | 0.18 |
| Asset Turnover Ratio (%) | 0.73 | 0.91 | 0.80 | 0.70 | 0.73 |
| Current Ratio (X) | 2.45 | 2.15 | 1.73 | 1.60 | 1.49 |
| Quick Ratio (X) | 1.62 | 1.33 | 1.10 | 0.87 | 0.81 |
| Inventory Turnover Ratio (X) | 4.01 | 2.01 | 1.79 | 1.71 | 1.88 |
| Dividend Payout Ratio (NP) (%) | 6.90 | 4.27 | 3.92 | 6.03 | 3.18 |
| Dividend Payout Ratio (CP) (%) | 5.51 | 3.56 | 2.96 | 3.41 | 2.13 |
| Earning Retention Ratio (%) | 93.10 | 95.73 | 96.08 | 93.97 | 96.82 |
| Cash Earning Retention Ratio (%) | 94.49 | 96.44 | 97.04 | 96.59 | 97.87 |
| Interest Coverage Ratio (X) | 41.43 | 33.94 | 21.55 | 10.72 | 9.10 |
| Interest Coverage Ratio (Post Tax) (X) | 23.14 | 22.44 | 13.51 | 5.73 | 5.50 |
| Enterprise Value (Cr.) | 15457.06 | 8068.90 | 2383.79 | 1534.95 | 2819.28 |
| EV / Net Operating Revenue (X) | 10.47 | 5.18 | 2.00 | 1.61 | 3.01 |
| EV / EBITDA (X) | 44.96 | 16.98 | 8.47 | 10.61 | 17.31 |
| MarketCap / Net Operating Revenue (X) | 10.55 | 5.20 | 1.95 | 1.39 | 2.87 |
| Retention Ratios (%) | 93.09 | 95.72 | 96.07 | 93.96 | 96.81 |
| Price / BV (X) | 10.22 | 6.32 | 2.34 | 1.58 | 3.43 |
| Price / Net Operating Revenue (X) | 10.55 | 5.20 | 1.95 | 1.39 | 2.87 |
| EarningsYield | 0.01 | 0.03 | 0.07 | 0.04 | 0.02 |
After reviewing the key financial ratios for Neuland Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 202.74. This value is within the healthy range. It has decreased from 233.89 (Mar 24) to 202.74, marking a decrease of 31.15.
- For Diluted EPS (Rs.), as of Mar 25, the value is 202.74. This value is within the healthy range. It has decreased from 233.89 (Mar 24) to 202.74, marking a decrease of 31.15.
- For Cash EPS (Rs.), as of Mar 25, the value is 252.44. This value is within the healthy range. It has decreased from 278.89 (Mar 24) to 252.44, marking a decrease of 26.45.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,181.32. It has increased from 993.65 (Mar 24) to 1,181.32, marking an increase of 187.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,181.97. It has increased from 994.31 (Mar 24) to 1,181.97, marking an increase of 187.66.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,144.79. It has decreased from 1,208.16 (Mar 24) to 1,144.79, marking a decrease of 63.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 266.48. This value is within the healthy range. It has decreased from 368.31 (Mar 24) to 266.48, marking a decrease of 101.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 215.67. This value is within the healthy range. It has decreased from 322.03 (Mar 24) to 215.67, marking a decrease of 106.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 268.46. This value is within the healthy range. It has decreased from 311.18 (Mar 24) to 268.46, marking a decrease of 42.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 201.63. This value is within the healthy range. It has decreased from 232.61 (Mar 24) to 201.63, marking a decrease of 30.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 201.63. This value is within the healthy range. It has decreased from 232.61 (Mar 24) to 201.63, marking a decrease of 30.98.
- For PBDIT Margin (%), as of Mar 25, the value is 23.27. This value is within the healthy range. It has decreased from 30.48 (Mar 24) to 23.27, marking a decrease of 7.21.
- For PBIT Margin (%), as of Mar 25, the value is 18.83. This value is within the healthy range. It has decreased from 26.65 (Mar 24) to 18.83, marking a decrease of 7.82.
- For PBT Margin (%), as of Mar 25, the value is 23.45. This value is within the healthy range. It has decreased from 25.75 (Mar 24) to 23.45, marking a decrease of 2.30.
- For Net Profit Margin (%), as of Mar 25, the value is 17.61. This value exceeds the healthy maximum of 10. It has decreased from 19.25 (Mar 24) to 17.61, marking a decrease of 1.64.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.61. This value is within the healthy range. It has decreased from 19.25 (Mar 24) to 17.61, marking a decrease of 1.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.06. This value is within the healthy range. It has decreased from 23.40 (Mar 24) to 17.06, marking a decrease of 6.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.23. This value is within the healthy range. It has decreased from 29.57 (Mar 24) to 16.23, marking a decrease of 13.34.
- For Return On Assets (%), as of Mar 25, the value is 11.93. This value is within the healthy range. It has decreased from 16.37 (Mar 24) to 11.93, marking a decrease of 4.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.08. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.08, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.91 (Mar 24) to 0.73, marking a decrease of 0.18.
- For Current Ratio (X), as of Mar 25, the value is 2.45. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.45, marking an increase of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 1.62. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.62, marking an increase of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.01. This value is within the healthy range. It has increased from 2.01 (Mar 24) to 4.01, marking an increase of 2.00.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.90. This value is below the healthy minimum of 20. It has increased from 4.27 (Mar 24) to 6.90, marking an increase of 2.63.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.51. This value is below the healthy minimum of 20. It has increased from 3.56 (Mar 24) to 5.51, marking an increase of 1.95.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.10. This value exceeds the healthy maximum of 70. It has decreased from 95.73 (Mar 24) to 93.10, marking a decrease of 2.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.49. This value exceeds the healthy maximum of 70. It has decreased from 96.44 (Mar 24) to 94.49, marking a decrease of 1.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 41.43. This value is within the healthy range. It has increased from 33.94 (Mar 24) to 41.43, marking an increase of 7.49.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.14. This value is within the healthy range. It has increased from 22.44 (Mar 24) to 23.14, marking an increase of 0.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,457.06. It has increased from 8,068.90 (Mar 24) to 15,457.06, marking an increase of 7,388.16.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 10.47. This value exceeds the healthy maximum of 3. It has increased from 5.18 (Mar 24) to 10.47, marking an increase of 5.29.
- For EV / EBITDA (X), as of Mar 25, the value is 44.96. This value exceeds the healthy maximum of 15. It has increased from 16.98 (Mar 24) to 44.96, marking an increase of 27.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.55. This value exceeds the healthy maximum of 3. It has increased from 5.20 (Mar 24) to 10.55, marking an increase of 5.35.
- For Retention Ratios (%), as of Mar 25, the value is 93.09. This value exceeds the healthy maximum of 70. It has decreased from 95.72 (Mar 24) to 93.09, marking a decrease of 2.63.
- For Price / BV (X), as of Mar 25, the value is 10.22. This value exceeds the healthy maximum of 3. It has increased from 6.32 (Mar 24) to 10.22, marking an increase of 3.90.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.55. This value exceeds the healthy maximum of 3. It has increased from 5.20 (Mar 24) to 10.55, marking an increase of 5.35.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neuland Laboratories Ltd:
- Net Profit Margin: 17.61%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.23% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.06% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.62
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 98.1 (Industry average Stock P/E: 52.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.08
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.61%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 11th Floor (5th Office Level), Phoenix IVY Building, Hyderabad Telangana 500033 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Davuluri Rama Mohan Rao | Executive Chairman |
| Mr. Davuluri Sucheth Rao | Vice Chairman & CEO |
| Mr. Davuluri Saharsh Rao | Vice Chairman & Mng.Director |
| Dr. Christopher M Cimarusti | Non Executive Director |
| Mr. Homi Rustum Khusrokhan | Ind. Non-Executive Director |
| Mr. Prasad Raghava Menon | Ind. Non-Executive Director |
| Mr. Sugata Sircar | Ind. Non-Executive Director |
| Ms. Pallavi Joshi Bakhru | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Neuland Laboratories Ltd?
Neuland Laboratories Ltd's intrinsic value (as of 29 December 2025) is 14681.53 which is 1.98% lower the current market price of 14,978.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 19,217 Cr. market cap, FY2025-2026 high/low of 19,748/10,060, reserves of ₹1,607 Cr, and liabilities of 2,534 Cr.
What is the Market Cap of Neuland Laboratories Ltd?
The Market Cap of Neuland Laboratories Ltd is 19,217 Cr..
What is the current Stock Price of Neuland Laboratories Ltd as on 29 December 2025?
The current stock price of Neuland Laboratories Ltd as on 29 December 2025 is 14,978.
What is the High / Low of Neuland Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Neuland Laboratories Ltd stocks is 19,748/10,060.
What is the Stock P/E of Neuland Laboratories Ltd?
The Stock P/E of Neuland Laboratories Ltd is 98.1.
What is the Book Value of Neuland Laboratories Ltd?
The Book Value of Neuland Laboratories Ltd is 1,263.
What is the Dividend Yield of Neuland Laboratories Ltd?
The Dividend Yield of Neuland Laboratories Ltd is 0.08 %.
What is the ROCE of Neuland Laboratories Ltd?
The ROCE of Neuland Laboratories Ltd is 18.7 %.
What is the ROE of Neuland Laboratories Ltd?
The ROE of Neuland Laboratories Ltd is 14.8 %.
What is the Face Value of Neuland Laboratories Ltd?
The Face Value of Neuland Laboratories Ltd is 10.0.